CA
NZ
UK
AU
IND
US
Black Diamond Therapeutics (NASDAQ:BDTX), trading as aPenny Stockat $2.04, fell 2.86% at last closing. The clinical-stage oncology company reported encouraging Phase 2 data for its lead cancer drug and refocused its resources on that program, backed by a cash position extending into 2028. For …
Bionano Genomics (NASDAQ:BNGO), trading as aPenny Stockat $1.22, closed flat at last closing. The maker of optical genome mapping technology grew its revenue and consumables sales in the second quarter and retired its convertible debt, even as it remained a small, lossmaking company. For …
Vir Biotechnology (NASDAQ:VIR) shares are trading higher, nearing their 52-week high, as investors continue to build on the momentum from strong second-quarter results, which showedEarnings Per Shareof $0.47 against a $0.33 consensus estimate, with revenue up sharply year over year.
Hims & Hers Health (NYSE:HIMS) shares are trading lower, giving back Monday's gain tied to news of the company's Australia expansion, as broader market weakness tied to surging oil prices, a U.S.-Iran conflict escalation, and rising Treasury yields pressures risk assets across sectors.
Kailera Therapeutics (NASDAQ:KLRA) shares are rebounding sharply after tumbling to a fresh 52-week low in the prior session, when the stock fell more than 12% and traded barely above its April IPO price, pressuring its marketCapitalizationto roughly its cash balance. The bounce comes amid …
MiniMed Group (NASDAQ:MMED) shares surged to a fresh 52-week high after the insulin delivery company reported fiscal Q1 2027 results that topped internal expectations, with net sales of $843 million, up 15.8% organically, driven by strong growth in pumps and continuous glucose monitors. The …
Moderna (NASDAQ:MRNA) shares are surging as investor enthusiasm builds around the company's oncology pipeline. The move follows late-August Phase 3 data showing that intensimeran autogene, Moderna's personalized cancer vaccine developed with Merck (NYSE:MRK), significantly reduced melanoma recurrence and metastasis risk when combined with Merck's …
Novartis (NYSE:NVS) shares rose sharply after the company announced that its oral drug remibrutinib outperformed an older treatment in reducing relapses in patients with a form of multiple sclerosis, boosting hopes the medicine could become a blockbuster product. The results mark the first success …
Novavax (NASDAQ:NVAX) shares are surging as investors respond to the company's late-August FDA emergency use authorization for its updated 2026-2027 protein-based Nuvaxovid COVID-19 vaccine formula, positioning the company as a non-mRNA alternative for the upcoming fall vaccination season.
Pulse Biosciences (NASDAQ:PLSE) shares are surging to fresh all-time highs, extending a powerful multi-month rally driven by clinical and regulatory momentum across the company's Nanosecond Pulsed Field Ablation platform. Investor enthusiasm has been fueled by faster-than-expected enrollment in the company's atrial fibrillation trial, alongside …
Please wait processing your request...